Rheum Cases & Guidelines https://t.co/0zI2KRuwxa https://t.co/TBw12LFh6i

ANA Pollution (2.06.2026 Dr. Jack Cush reviews the news, journal articles, and regulatory news from this past week on RheumNow. https://t.co/cfEjEr36Tb https://t.co/OJbE6P3k6p

RT @ericdeinMD Mucosal Hypothesis RA #RNL26 Demoruelle ACPA can predate RA development Nam et al: non-specific jt pain: 42% developed RA in 12 mos Circiumaro et al: MSK complaints 38% devel RA in 36 mo APIPPRA: 29% at 12 mo, 37% at 24 mo, StopRA 18% in 12 mo, 33% at 36 mo https://t.co/JYiWmn0N0g

RT @richardPAconway Dr Sparks. RA-ILD is common. Pooled prevalence of 11% from recent meta-analysis. Less common than SSc or IIM, but more frequent than we think! #RNL26 https://t.co/TCsDfeQjZC

RT @ericdeinmd Mortality risk in RA #RNL26 Myasoedova Most common mortality: 1.5-1.6x increase risk CVD 2-3x increase risk ILD +ACPA increases risk in both https://t.co/Luwyy6UFg6

RT @ericdeinmd Mortality risk in RA #RNL26 Myasoedova Premature deaths in up to 1/4 of pts Decline in mortality in RA after year 2000 Full siblings of RA also high mortality (shared genetic or environ factors affect risk?) Risks: Seropositivity, esp ACPA, CRP, extra-artic https://t.co/ytm6odmtgR

FDA vs. Amgen: At Odds Over Avacopan The FDA has requested that Amgen voluntarily withdraw avacopan (Tavneos), a treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis, but the company said it has no plans to pull the drug from the market. https://t.co/v5AYm6r53W

ACR Applauds Recent Government Funding The American College of Rheumatology (ACR) praised the recent Congressional CY 26 funding package, highlighting its provisions to extend Medicare telehealth payment flexibilities, enhance transparency in pharmacy benefit management, and https://t.co/gr3X7RRGLN

SGLT2 Inhibitors in Gout - Better Outcomes, Fewer Meds Natalie McCormick, PhD (RACER Center, Mass General Brigham), led a new Diabetes Care study on gout-related medication use after starting SGLT2 inhibitors in patients with gout and type 2 diabetes. https://t.co/BFJB3OY2L3 https://t.co/63Bu4t6LYM

REcently published SMILE study looked at the potential of HCQ (vs PBO) to prevent SLE in at risk people. Had to be ANA+ and 1-2 SLICC criteria at entry. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/s4Mzoec5ga

Factors that may augment future development of SLE - includes Vitamin D levels, poor sleep, EBV reactivation & social determinants of health. Can you Prevent SLE? Dr. David Karp lecturing at UTSW @drdavidkarp @utswrheum https://t.co/2J1JBjeXKU

Methotrexate intolerance in rheumatoid arthritis A current large rheumatoid arthritis (RA) cohort study from Cairo assessed methotrexate (MTX) use and found over half were MTX intolerant and a third of patients were noncompliant with MTX. https://t.co/ODiVqUXBb9 https://t.co/QwmNkrjvn6